EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab

Maitha Al Hosani, Noorah Al Hosani, Mohamed Nasir Alzaabi, Maryam A Alahmad, Nadeen Mamon Omar, Camille Conde Oribiana, Enas Fouad Ahmed, Ishtiaq Ahmed, Kishore Kumar Chitra Kumar, Sofia Hanif, Khalid Izzeldin Elfatih Barakat, Khalid Osman Elamin Elsayed, Mohammed Nabil Quraishi

Crohn's & Colitis 360 · 2026-06-19

DOI: 10.1093/crocol/otag061 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background No head-to-head trials compare selective interleukin-23 inhibitors in Crohn’s disease (CD), leaving clinicians without direct evidence to guide treatment selection. We aimed to evaluate real-world induction effectiveness of guselkumab in CD and perform propensity score-matched (PSM) comparisons against risankizumab. Methods This prospective multicentre study included adults with moderate-to-severe CD initiating guselkumab in the United Arab Emirates. The primary outcome was clinical remission at Week 12 (Harvey-Bradshaw Index <5). Full propensity score matching between guselkumab and risankizumab cohorts controlled for 12 covariates including disease phenotype, baseline endoscopic and biochemical activity, surgical history, and current smoking status. Results Fifty-one guselkumab and 60 risankizumab patients were included. In the guselkumab cohort, 71% were advanced therapy-exposed with a median of 2 prior advanced therapies. At Week 12, clinical remission was achieved in 51% (26/51) and clinical response in 86% (44/51). Median CRP decreased from 8.5 to 3.0 mg/L (p = 0.002) and faecal calprotectin from 216 to 80 ug/g (p < 0.001). Effectiveness was consistent regardless of prior treatment history. On univariable analysis, higher baseline HBI (OR 0.77, p = 0.011), SES-CD (OR 0.87, p = 0.049), and CRP (OR 0.94, p = 0.019) were associated with lower remission likelihood. Maintenance dosing was 100 mg Q8W in 73% and 200 mg Q4W in 27%. PSM analysis demonstrated comparable clinical remission (51% vs 50%, p > 0.9) and clinical response (86% vs 87%, p = 0.87) between guselkumab and risankizumab, with no significant between-group biomarker differences. Conclusions Guselkumab demonstrated robust real-world induction effectiveness comparable to risankizumab across clinical and biochemical outcomes. These findings warrant confirmation in larger, longer-term comparative studies with endoscopic endpoints.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →